

Caution: For Laboratory Use. A research reagent for research purposes only

## human CGRP<sub>1</sub> Receptor (CRLR + RAMP1) Aequorin Cell Line

**Product No.:** ES-420-A

**Lot No.:** 2531494

### Material Provided

|                |  |
|----------------|--|
| <b>Cells:</b>  | 2 x 1 mL frozen aliquots (ES-420-AV)                 |
| <b>Format:</b> | ~2.5 x 10 <sup>6</sup> cells / mL in freezing medium |

### Product Information

|   |   |
|---|---|
| <b>Cellular Background:</b>                         | CHO-K1  |
| <b>Cell Line Development:</b>                       | Our proprietary bicistronic expression plasmid containing the sequence coding for the human Calcitonin Receptor-like Receptor (CRLR) was transfected in CHO-K1 cells stably expressing the mitochondrially targeted Aequorin. Geneticin-resistant cells were selected, and the pool of cells was transfected with another bicistronic expression plasmid containing the sequence coding for the receptor activity modifying protein 1 (RAMP1). Blasticidin-resistant cells were selected, and the pool of cells was transfected with another bicistronic expression plasmid containing the sequence coding for the G <sub>αq/s(5)</sub> chimaeric protein. Zeocin-resistant clones were obtained by limit dilution and compared for their response to a reference agonist using the AequoScreen® assay. |
| <b>DNA Sequence:</b>                                | Identical to coding sequence of GenBank NM_005795.4 (CRLR) and NM_005855.2 (RAMP1).   |
| <b>Corresponding Protein Sequence:</b>              | Identical to GenBank NP_005786.1 (CRLR) and NP_005846.1 (RAMP1).  |
| <b>Receptor expression level (B<sub>MAX</sub>):</b> | Estimated to be 1.8 pmol/mg protein, using [ <sup>125</sup> I]hCGRP.  |
| <b>K<sub>D</sub> for the above radioligand:</b>     | 7.2nM   |
| <b>Shipping Conditions:</b>                         | Shipped on dry ice. Please ensure dry ice is still present in the package upon receipt or contact Customer Support.   |
| <b>Storage Conditions:</b>                          | Store in liquid nitrogen (vapor phase) immediately upon receipt.  |

## Quality Control

The EC<sub>50</sub> for a reference agonist was determined in an AequoScreen® assay performed on a MicroLumat Plus (Berthold) instrument. A mycoplasma test was performed using MycoAlert® Mycoplasma (Lonza) detection kit. We certify that these results meet our quality release criteria.

**α-CGRP (human) (EC<sub>50</sub>):** 3.1 nM

**Stability:** Cells were kept in continuous culture for at least 60 days and showed no decrease in functional response (EC<sub>50</sub>, E<sub>max</sub>).

**Mycoplasma:** This cell line tested negative for mycoplasma.

## Assay Procedures

We have shown for many of our GPCR cell lines that freshly thawed cells respond with the same pharmacology as cultured cells. All of our products validated in this way are available as frozen ready-to-use cells in our catalogue. PerkinElmer also offers a custom service for the preparation of large quantities of frozen cryopreserved cells either from a catalogue cell line or a customer's own cell line. This demonstrates that cells can be prepared and frozen in advance of a screening campaign simplifying assay logistics.

## Recommended Cell Culture Conditions (CHO-K1)

- The recommended media catalogue number and supplier reference information are listed in this Product Technical Data Sheet (last page). Media composition is specifically defined for each cell type and receptor expression selection. The use of incorrect media or component substitutions can lead to reduced cell viability, growth issues and/or altered receptor expression.
- Cells undergo major stress upon thawing, and need to adapt to their new environment which may initially affect cell adherence and growth rates. The initial recovery of the cells, and initial doubling time, will vary from laboratory to laboratory, reflecting differences in the origin of culture media and serum, and differences in methodology used within each laboratory.
- For the initial period of cell growth (i.e. until cells have reached Log-phase, typically 4-10 days), we strongly recommend removal of the antibiotics (G418, Zeocin™, Puromycin, Blastidicin, Hygromycin, Penicillin and Streptomycin) from the culture media. Immediately after thawing, cells may be more permeable to antibiotics, and a higher intracellular antibiotic concentration may result as a consequence. Antibiotics should be re-introduced when cells have recovered from the thawing stress.

**Growth Medium:** Ham's F-12, 10% FBS, 400 µg/mL Geneticin (CRLR Receptor expression selection), 10 µg/mL Blastidicin (RAMP1 expression selection), 250 µg/mL Puromycin (Aequorin expression selection), and 10 µg/mL Zeocin ( $G_{\alpha q/s(5)}$  expression selection).

**Freezing Medium:** Ham's F-12, 10% FBS with 10% DMSO, without selection agents.

**Thawing Cells:** Using appropriate personal protective equipment, rapidly place the frozen aliquot in a 37°C water bath (do not submerge) and agitate until its content is thawed completely. Immediately remove from water bath, spray aliquot with 70% ethanol and wipe excess. Under aseptic conditions using a sterile pipette, transfer content to a sterile centrifuge tube containing 10 mL growth medium without antibiotics, pre-warmed at 37°C, and centrifuge (150 x g, 5 min). Discard supernatant using a sterile pipette. Resuspend cell pellet in 10 mL of pre-warmed growth medium without antibiotics by pipetting up and down to break up any clumps, and transfer to an appropriate culture flask (e.g. T-25, T-75 or T-175, see recommended seeding density below). Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO<sub>2</sub>.

**Recommended Seeding Density:**


|            |                                       |
|------------|---------------------------------------|
| Thawing:   | 15 000 – 33 000 cells/cm <sup>2</sup> |
| Log-phase: | 11 000 – 15 000 cells/cm <sup>2</sup> |

**Troubleshooting:** Initial doubling time can vary between 18 and 96 hours (Average = 25 hours). If cells are still not adhering after 48 hours or grow very slowly, we recommend maintaining the cells in culture and not replacing the media before 5-6 days (cells secrete factors that can help with adherence and growth). If confluence is still <50% after 5-6 days, it is recommended that you replace the media with fresh media (without antibiotics). Do not passage the cells until they reach 80-90% confluence (Log-phase). If cells have not recovered after 10-12 days, please contact our Technical Support.

**Culture Protocol:** Under aseptic conditions, cells are grown to 80% confluence (Log-phase) and trypsinized (0.05% trypsin / 0.5 mM EDTA in calcium and magnesium-free PBS). See recommended seeding density for Log-phase above.

**Banking Protocol:** Cells are grown to 70-80% confluence (Log-phase). Under aseptic conditions, remove medium and rinse the flask with an appropriate volume of calcium and magnesium-free PBS (example 10 mL for T-175). Trypsinize (0.05% trypsin / 0.5 mM EDTA in calcium and magnesium-free PBS) to detach cells (example 5 mL for T-175), let stand 5-10 min at 37°C. Add fresh, room temperature growth medium (without antibiotics) to stop trypsinization and dilute EDTA (example 10 mL for T-175). Transfer cells to a sterile centrifuge tube and centrifuge (150 x g, 5 min). Discard supernatant using a sterile pipette. Resuspend cell pellet in ice-cold freezing medium by pipetting up and down to break up any clumps. Count cells and rapidly aliquot at the selected cell density (e.g. 2.5 x 10<sup>6</sup> cells/mL) in sterile polypropylene cryovials. Use appropriate material to ensure slow cooling (about -1°C/min) until -70°C. Transfer vials into a liquid nitrogen tank (vapour phase) for storage.


## Typical Product Data – AequoScreen® Assay



| Agonist        | EC <sub>50</sub> (M)   | % of Digitonin response |
|----------------|------------------------|-------------------------|
| α-CGRP (human) | 1.8 x 10 <sup>-8</sup> | 67                      |

**Figure 1: Agonist Response in AequoScreen® assay**

An agonist dose-response experiment was performed in 96-well format using 25 000 cells/well. Luminescence was measured on a MicroLumat Plus (Berthold). Data from a representative experiment are shown.




| Antagonist | IC <sub>50</sub> (M)   |
|------------|------------------------|
| B10647603  | ~3 x 10 <sup>-11</sup> |

**Figure 2: Antagonist Response in AequoScreen® assay**

An antagonist dose-response experiment was performed in 96-well format using 25 000 cells/well with the reference agonist (α-CGRP) injected at a final concentration equivalent to the EC<sub>80</sub> (55 nM). Luminescence was measured on a MicroLumat Plus (Berthold). Data from a representative experiment are shown.

## Typical Product Data – Calcium Assay (Fluorescence)




| Agonist        | EC <sub>50</sub> (M)   |
|----------------|------------------------|
| α-CGRP (human) | 4.4 x 10 <sup>-8</sup> |

**Figure 3. Agonist Response in Fluo-4 Calcium assay**

An agonist dose-response experiment was performed in 96-well format using 25 000 cells/well. Fluorescence was measured on a FDSS6000 (Hamamatsu Photonics). Data from a representative experiment are shown.

## Typical Product Data –Radioligand Binding Assay (Filtration)



**Figure 4: Saturation Binding Assay Curve (Filtration)**

A saturation binding assay was performed in polyethylene MiniSorp (Nunc) tubes using 5 µg membranes/tube. Counts per minute (CPM) were measured on the TopCount®. Data from a representative experiment are shown.

## AequoScreen® Assay Procedure (MicroBeta® JET)

**Assay Buffer:** DMEM / HAM's F12 with HEPES, without phenol red (Invitrogen # 11039-021) + 0.1 % protease-free BSA (from 10% solution sterilized by filtration at 0.22 µm). Store at 4°C.

**Coelenterazine h:** To prepare a 500 µM Coelenterazine h stock solution, solubilize 250 µg of Coelenterazine h (Promega # S2011 or Invitrogen # C6780) in 1227 µL methanol. Store at -20°C in the dark.

**Digitonin:** To prepare a 50 mM Digitonin stock solution, dissolve 1 g of Digitonin (Sigma # D5628) in 16.27 mL of DMSO. Aliquot and store at -20°C.

|                                    |   |
|------------------------------------|---|
| 1. Cell Culture and Harvesting:    | Grow cells (mid-log phase) in culture medium without antibiotics for 18 hours, Detach gently with PBS / 0.5 mM EDTA, pH 7.4, Recover by centrifugation. Resuspend in Assay Buffer at a concentration of 3x10 <sup>5</sup> cells/mL.   |
| 2. Coelenterazine Loading:         | Under sterile conditions, add "Coelenterazine h" at a final concentration of 5 µM to the cell suspension, mix well. Incubate at room temperature protected from light and with constant gentle agitation for at least 4 hours (incubation can be extended overnight).   |
| 3. Cells Dilution:                 | Dilute cells 3x in assay buffer and incubate as described above for 60 min.   |
| 4. Ligands and plates preparation: | Prepare serial dilutions of ligands in assay buffer (2x concentration for agonists, 2x concentration for antagonists). Dispense 50 µL of diluted ligand in a 96-well Optiplate™. <i>Note: Assay can be miniaturized to 384-well and 1536-well formats.</i>  |
| 5. Agonist Mode Reading:           | Using the reader's automatic injection system, inject 50 µL of cells (i.e. 5 000 cells) per well and immediately record relative light emission for 20-40 seconds. Digitonin at a final concentration of 100 µM in assay buffer is used in control wells to measure the receptor independent cellular calcium response. |
| 6. Antagonist Mode Reading:        | After 15 minutes of incubation of the cells with the ligand, using the reader's automatic injection system, inject 50 µL of the reference agonist at a final concentration equivalent to the EC <sub>80</sub> and immediately record relative light emission for 20-40 seconds.   |
| 7. Data Analysis:                  | Sigmoidal dose-response curves are generated using average Luminescent Counts Per Second (LCPS) recorded for 20-40 sec immediately after cells are mixed with the agonist in agonist mode or the EC <sub>80</sub> of a reference agonist in antagonist mode.  |

### Important Notes:

- Temperature should remain below 25°C during the coelenterazine loading of the cells, and until using the cells for the readings. Excessive heating by the cell stirrer for example will result in signal loss.
- Depending on (1) sensitivity of the reader used, (2) plate format used, and (3) assay characteristics wanted, it is possible to load cells at (a) different concentrations of cells and coelenterazine, (b) with different subsequent dilution factors, and (c) using different cell numbers per well. This is part of the validation work when importing an assay to a new reader.
- For tips and examples on running AequoScreen® assays on different readers, please refer to the AequoScreen® Starter Kit Manual available at [www.perkinelmer.com/CellLines](http://www.perkinelmer.com/CellLines).

## Calcium Assay Procedure (Fluorescence)

**Dye solution:** 5  $\mu$ M Fluo-4 AM (Molecular Probes, P-6867), 1 mg/mL Pluronic acid in Assay Buffer

**Assay Buffer:** 2.5 mM Probenicid, 0.1% BSA, 0.05% Gelatin, 135 mM NaCl, 5 mM KCl, 1.8 mM CaCl<sub>2</sub>, 1 mM MgCl<sub>2</sub>, 10 mM HEPES, 5.6 mM Glucose, pH 7.4

**Controls:** Maximal Signal: 0.4% Triton X-100 (0.2% final) in Assay Buffer  
Minimum signal: 0.4% Triton X-100 (0.2% final), 20 mM EGTA (10 mM final) in Assay Buffer

**Reader:** FDSS 6000 (Hamamatsu Photonics), Excitation 480 nm / Emission 520 to 560 nm, 96-well

| Day 1   |  |   |   |
|---|--|---|---|
| 1. Cell Culture and Harvesting:   | Grow cells (mid-log phase) in culture medium without antibiotics for 18 hours, Detach gently with PBS / 0.5 mM EDTA, pH 7.4, Recover by centrifugation, Resuspend in medium without antibiotics at $2.5 \times 10^5$ cells/mL.   |   |   |
| 2. Cell Seeding   | Distribute 100 $\mu$ L (i.e. 25,000 cells) in each well of a 96 well black, clear bottom TC sterile plate, incubate overnight in a cell culture incubator (37°C, 5% CO <sub>2</sub> ).   |   |   |
| Day 2   |  |   |   |
| 3. Cell Loading   | Remove the media, and add 100 $\mu$ L/well of Dye solution.  |   |   |
| 4. Incubation   | Incubate the assay plate for 1 hour at 37°C in a cell culture incubator.   |   |   |
| 5. Ligands and compound plates preparation:   | Prepare serial dilutions of 2x concentrated ligands in Assay Buffer, Dispense 100 $\mu$ L/well of diluted ligand in a 96-well plate.<br><i>Note: Assay can be miniaturized to 384-well format.</i>   |   |   |
| 6. Dye Washing  | Drain the media and wash the wells twice with 100 $\mu$ L/well buffer A,   |   |   |
| 7. Buffer/Antagonist addition   | <table border="1" style="width: 100%;"> <tr> <td style="width: 50%;"><b>Agonist assay:</b><br/>Add Assay Buffer to make a total of 50 <math>\mu</math>L</td> <td style="width: 50%;"><b>Antagonist Assay:</b><br/>Add 2x antagonist dilution in Assay Buffer to make a total of 50 <math>\mu</math>L</td> </tr> </table>   | <b>Agonist assay:</b><br>Add Assay Buffer to make a total of 50 $\mu$ L   | <b>Antagonist Assay:</b><br>Add 2x antagonist dilution in Assay Buffer to make a total of 50 $\mu$ L  |
| <b>Agonist assay:</b><br>Add Assay Buffer to make a total of 50 $\mu$ L   | <b>Antagonist Assay:</b><br>Add 2x antagonist dilution in Assay Buffer to make a total of 50 $\mu$ L   |   |   |
| 8. Equilibration  | Incubate the plate for 20 min at room temperature in the dark.   |   |   |
| 9. Plate Reading:   | <table border="1" style="width: 100%;"> <tr> <td style="width: 50%;">Using the reader's injection system, inject 50 <math>\mu</math>L per well of 2x agonist solutions in Assay Buffer, and immediately record relative light emission for 90 seconds.</td> <td style="width: 50%;">Using the reader's injection system, inject 50 <math>\mu</math>L per well of 2x concentrated reference agonist in Assay Buffer (final EC<sub>80</sub> concentration), and immediately record relative light emission for 90 seconds.</td> </tr> </table> | Using the reader's injection system, inject 50 $\mu$ L per well of 2x agonist solutions in Assay Buffer, and immediately record relative light emission for 90 seconds. | Using the reader's injection system, inject 50 $\mu$ L per well of 2x concentrated reference agonist in Assay Buffer (final EC <sub>80</sub> concentration), and immediately record relative light emission for 90 seconds. |
| Using the reader's injection system, inject 50 $\mu$ L per well of 2x agonist solutions in Assay Buffer, and immediately record relative light emission for 90 seconds. | Using the reader's injection system, inject 50 $\mu$ L per well of 2x concentrated reference agonist in Assay Buffer (final EC <sub>80</sub> concentration), and immediately record relative light emission for 90 seconds.  |   |   |
| 10. Data Analysis:  | The fluorescent signal is expressed as the ratio relative to the first measurement (i.e. before dispensing), and the maximal value of this ratio during the measurement interval is used to draw sigmoidal dose-response curves.   |   |   |

### Important Notes:

- Probenicid is prepared as a 250 mM solution in a 50:50 mixture of 1N NaOH : Assay Buffer.

## Membrane Radioligand Binding Assay Procedure (Filtration)

*Note: The following are recommended assay conditions and may differ from the conditions used to generate the typical data shown in the above section.*

**Assay Buffer:** 50 mM TRIS-HCl pH 7.4, 5 mM MgCl<sub>2</sub>, 0.5% BSA, 0.05% Tween

**Wash Buffer:** 50 mM TRIS-HCl pH 7.4 (ice cold)

**Radioligand:** [<sup>125</sup>I]hCGRP (PerkinElmer # NEX354)

**Filters:** Unifilter 96 GF/B (PerkinElmer # 6005177)

### Membrane Binding Protocol:

Binding assays were performed in 200 µL total volume according to the following conditions. All dilutions are performed in assay buffer:

|   |  |
|---|--|
| 1. Membrane dilution:                         | 0.4 µg of membranes per well, diluted in order to dispense 150 µL/well. Keep on ice.   |
| 2. Assembly on ice<br>(in 96 Deep well plate) | <ul style="list-style-type: none"> <li>• 25 µL of assay buffer or of unlabeled ligand (α-CGRP (human), 4 µM final) for determination of non specific binding</li> <li>• 25 µL of radioligand at increasing concentrations (see figure 4)</li> <li>• 150 µL of diluted membranes</li> </ul> |
| <b>Saturation Binding:</b>                    |  |
| <b>Competition Binding:</b>                   | <ul style="list-style-type: none"> <li>• 25 µL competitor ligand at increasing concentrations</li> <li>• 25 µL of radioligand (0.3 nM final)</li> <li>• 150 µL of diluted membranes</li> </ul>   |
| 3. Incubation:                                | 30 min at 25 °C.   |
| 4. Filters preparation:                       | GF/B filters were presoaked in 0.5 % PEI at room temperature for at least 30 min.  |
| 5. Filtration:                                | Aspirate and wash 9 x 500 µL with ice cold wash buffer using a FilterMate Harvester (PerkinElmer).   |
| 6. Counting:                                  | Add 30 µL/well of MicroScint™-O (PerkinElmer # 6013611), cover filter with a TopSeal-A (PerkinElmer # 6050195) and read on a TopCount® (PerkinElmer).  |



## References

1. Dupriez VJ, Maes K, Le Poul E, Burgeon E, Dethoux M. (2002) Aequorin-based functional assays for G-protein-coupled receptors, ion channels, and tyrosine kinase receptors. *Receptors Channels* 8:319-30
2. Rizzuto R, Simpson AWM, Brini M, Pozzan T. (1992) Rapid changes of mitochondrial  $Ca^{2+}$  revealed by specifically targeted recombinant aequorin. *Nature* 358:325-327.
3. Stables J., Green A., Marshall F., Fraser N., Knight E., Sautern M., Milligan G., Lee M., Rees S. (1997) A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. *Anal. Biochem.* 252:115-126.
4. Conklin BR, Farfel Z, Lustig KD, Julius D, Bourne HR. (1993) Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. *Nature* 363:274-276.
5. B. Fluehmann, Muff R, Hunziker W, Fischer JA, Born W. et al., (1995) A human orphan calcitonin receptor-like structure. *BBRC* 206 :341-347.
6. S. Kapas and Clark AJ. (1995) Identification of an orphan receptor gene as a type 1 calcitonin gene-related peptide receptor. *BBRC* 217:832-838.
7. N. Aiyar, Rand K, Elshourbagy NA, Zeng Z, Adamou JE, Bergsma DJ, Li Y. (1996) A cDNA encoding the calcitonin gene-related peptide type 1 receptor. *J. Biol. Chem* 271:11325-11329.
8. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* 393:333-339.
9. Kuwasako K, Shimekake Y, Masuda M, Nakahara K, Yoshida T, Kitaura M, Kitamura K, Eto T, Sakata T (2000) Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. *J Biol Chem.* 275:29602-29609.

## Materials and Instrumentation

The following tables provide the references of compounds and reagents used for the characterization of the human CGRP<sub>1</sub> Receptor Aequorin cell line, as well as some advice on how to use these compounds:

**Table 1. References of compounds used for functional characterization and binding assays**

| Name                     | Provider                     | Cat n° | Working Stock Solution                  |
|--------------------------|------------------------------|--------|---|
| α-CGRP (human)           | Bachem                       | H-1470 | 0,2 mM in PBS / 0.1 % protease-free BSA |
| B10647603                | (not commercially available) |        |   |
| [ <sup>125</sup> I]hCGRP | PerkinElmer                  | NEX354 | N/A                                     |

**Table 2. References of cell culture media and additives.**

*Note: The table below lists generic media and additives typically used for PerkinElmer cell lines. For product specific media and additives, please refer to the "Recommended Cell Culture Conditions" section.*

| Name  | Provider            | Cat n°     |
|---|---------------------|------------|
| HAM's F-12  | Hyclone             | SH30026.02 |
| DMEM  | Hyclone             | SH30022.02 |
| UltraCHO (serotonin receptors)                                | BioWitthaker        | 12-724-Q   |
| EMEM  | BioWitthaker        | 06-174G    |
| DHFR <sup>-</sup> HAM's F-12 (for DHFR deficient cell lines)  | Sigma               | C8862      |
| FBS   | Wisent              | 80150      |
| FBS dialyzed  | Wisent              | 80950      |
| G418 (geneticin)  | Wisent              | 400-130-IG |
| Zeocin  | Invitrogen          | R25005     |
| Blasticidin   | invitrogen          | R210-01    |
| Puromycin   | Wisent              | 400-160-EM |
| Standard HBSS (with CaCl <sub>2</sub> and MgCl <sub>2</sub> ) | GIBCO               | 14025      |
| HEPES   | MP Biomedicals, LLC | 101926     |
| BSA, Protease-free  | Sigma               | A-3059     |
| PEI   | Sigma               | P3143      |
| Trypsin-EDTA  | Hyclone             | SH30236.02 |
| Sodium Pyruvate   | GIBCO               | 11360      |
| L-Glutamine   | GIBCO               | 25030      |
| NEAA (non-essential amino acids)                              | GIBCO               | 11140      |

Please visit our website: [www.perkinelmer.com/CellLines](http://www.perkinelmer.com/CellLines) for additional information on materials, microplates and instrumentation.

**This product is not for resale or distribution except by authorized distributors.**

PerkinElmer, Inc.  
940 Winter Street  
Waltham, MA 02451 USA  
P: (800) 762-4000 or  
(+1) 203-925-4602  
[www.perkinelmer.com](http://www.perkinelmer.com)



For a complete listing of our global offices, visit [www.perkinelmer.com/ContactUs](http://www.perkinelmer.com/ContactUs)

Copyright ©2009, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners.